IMMUNO-ONCOLOGY AND ANTIBODY BASED THERAPIES
Immuno-oncology is a type of immunotherapy that is specifically targeted to use the body’s natural defenses (immune system) to fight cancer.
The first immuno-oncology treatment was approved in 2010, and since then it has proven to be an effective treatment for melanoma and lymphoma, as well as lung, kidney and bladder cancer. By stimulating the immune system, the body is able to fight back, and destroy cancer cells while leaving the rest of the body unharmed.
The type of therapeutics defined as immuno-oncology drugs include, but are not limited to, monoclonal antibodies, bi-specific antibodies, antibody-drug-conjugates (ADC) and often include combination therapies. Therapies may often have an agonistic effect as well as stimulation and effector function.
Our team of Bioanalytical experts have worked with several oncology projects and faced many of the challenges that can occur in these complex projects. This includes assay development of PK and ADA assays, as well as assays to measure target protein and relevant biomarkers. We have the experience of using multi-plex panels with inflammatory biomarkers and will tailor the validation of the assays so that they that are fit for purpose in the context of use.
Whether you want to test your therapy in a cell biology assay consisting of the elements of the tumor microenvironment, or in models using real patient tissue, we are here to help!